What science can do

AstraZeneca Annual Report and Form 20-F Information 2015
AstraZeneca is a global, science-led biopharmaceutical business... ...with an on-market portfolio in our chosen therapy areas.

Respiratory, Inflammation and Autoimmunity

$4,987m
Product Sales
2014: $5,063m
2013: $4,677m

Cardiovascular and Metabolic diseases

$9,489m
Product Sales
2014: $9,802m
2013: $8,830m

Oncology

$2,825m
Product Sales
2014: $3,027m
2013: $3,193m

Infection, Neuroscience and Gastrointestinal

$6,340m
Product Sales
2014: $8,203m
2013: $9,011m

Highlights

> Respiratory sales up by 7%, including 25% in Emerging Markets, before completion of the acquisition of Takeda’s respiratory business
> Sales of Symbicort down by 3%

> Brilinta/Brilique sales up by 44%, including 64% in the US
> Diabetes sales up by 26%, including 76% in Emerging Markets
> Sales of Crestor fell by 3% reflecting competition from generic statins and pricing pressure

> Oncology sales up by 7%
> New Oncology included for the first time (comprising Lynparza, Iressa (US) and Tagrisso)
> Lynparza launched in 15 markets and sales of $94 million

> Sales of Nexium declined by 26%, including 52% in the US following loss of exclusivity
> Sales of Seroquel XR fell by 12% and Synagis fell by 26%

We have distinctive R&D capabilities, a growing late-stage pipeline...

NMEs in Phase III, pivotal Phase II or under regulatory review

15

Small molecules
Biologics
Immunotherapies
Protein engineering
Devices

Personalised healthcare and translational science capabilities

Therapy Area Review from page 24 and Research and Development from page 42
...and a strong global commercial presence, with strength in Emerging Markets.

### North America

- **Product Sales**
  - 2014: $10,710m
  - 2013: $10,328m

### Europe

- **Product Sales**
  - 2014: $6,638m
  - 2013: $6,658m

### International and Japan

- **Product Sales**
  - 2014: $8,747m
  - 2013: $8,725m

### Employees

- **North America**: 7,600
- **Europe**: 5,900
- **International and Japan**: 21,900

### Highlights

- Sales in the US declined by 6% reflecting entry of generic *Nexium* products and adverse *Synagis* guideline changes.
- Favourable performances were delivered by *Brilinta*, *Farxiga*, *Bydureon* and *Lynparza* as well as the acquired Respiratory medicines, *Tudorza* and *Daliresp*.
- Sales in Canada grew by 4%.
- Sales declined by 6%.
- Strong growth for Diabetes medicines was offset by generic competition facing *Crestor* and *Seroquel XR*.
- 14% decline in *Symbicort* sales reflected adverse pricing movements driven by competition from analogues in key markets.
- Emerging Markets revenue grew by 12% to $5,822 million, including China sales growth of 15%.
- Sales in Japan grew by 4% to $2,020 million.
- Opened facility in Russia.

### Business Review from page 42

Our talented employees are committed to achieving our Purpose in a sustainable way...

- **61,500** employees worldwide
- **8,900** employees in R&D
- **12,500** employees in Manufacturing and Supply

Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres

- **Cambridge, UK**
- **Gaithersburg, Maryland US**
- **Gothenburg, Sweden**

...and our disciplined capital allocation enables commitment to a progressive dividend.

- **Net cash shareholder distributions**
  - Increased to $3,443 million
- **Dividend per Ordinary Share**
  - Unchanged

### Net cash shareholder distributions

<table>
<thead>
<tr>
<th>Year</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$3,443m</td>
</tr>
<tr>
<td>2014</td>
<td>$2,342m</td>
</tr>
<tr>
<td>2013</td>
<td>$2,979m</td>
</tr>
</tbody>
</table>

### Dividend per Ordinary Share

<table>
<thead>
<tr>
<th>Year</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$2.80</td>
</tr>
<tr>
<td>2014</td>
<td>$2.80</td>
</tr>
<tr>
<td>2013</td>
<td>$2.80</td>
</tr>
</tbody>
</table>

All growth rates at CER.
All employee numbers are approximate as at 31 December 2015.